7062-40-0

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-2-METHOXYPHENYLACETONITRILE is used as a synthetic intermediate for the production of various pharmaceutical compounds. Its unique molecular structure allows for the creation of a wide range of derivatives with potential therapeutic applications, making it a valuable asset in the development of new drugs.
Used in Chemical Synthesis:
In the field of organic chemistry, 5-BROMO-2-METHOXYPHENYLACETONITRILE is used as a key building block for the synthesis of various organic compounds. Its versatile structure enables chemists to perform a range of reactions, such as substitution, addition, and condensation, to create new molecules with diverse properties and applications.
Used in Research and Development:
5-BROMO-2-METHOXYPHENYLACETONITRILE is also utilized in research and development laboratories for the exploration of new chemical reactions and the development of innovative synthetic methods. Its unique structure and reactivity make it an ideal candidate for studying various aspects of organic chemistry, including reaction mechanisms, stereochemistry, and catalyst design.

InChI:InChI=1/C21H22N4O2S/c1-4-8-28-20-24-18-17(19(27)25-20)15(12-6-5-7-22-11-12)16-13(23-18)9-21(2,3)10-14(16)26/h4-7,11,15H,1,8-10H2,2-3H3,(H2,23,24,25,27)

Upstream product

• 7017-52-9 4-bromo-2-(chloromethyl)-1-methoxybenzene 
• 151-50-8 potassium cyanide 
• 7035-03-2 2-methoxy-benzeneacetonitrile 
• 2316-64-5 5-bromo-2-hydroxybenzyl alcohol 
• 25016-01-7 5-bromo-2-methoxybenzaldehyde 
• 80866-82-6 5-bromo-2-methoxy-benzyl alcohol 

Downstream Products

• 163813-58-9 N-<2-(2-methoxy-5-bromophenyl)ethyl>acetamide 
• 73775-47-0 2-(2-Methoxy-5-bromobenzyl)-2-imidazoline hydrochloride 
• 73775-42-5 2-(5-Bromo-2-methoxy-phenyl)-acetamidine; hydrochloride 
• 149488-99-3 2-(2-methoxy-5-bromophenyl)-1-aminoethane 
• 73775-39-0 2-(5-Bromo-2-methoxy-phenyl)-acetimidic acid ethyl ester; hydrochloride 
• 7017-48-3 2-(5-bromo-2-methoxyphenyl)acetic acid 
• 863562-62-3 5-bromo-2-methoxyphenylacetic acid ethyl ester 
• 294860-58-5 methyl 2-(5-bromo-2-methoxyphenyl)acetate 

Relevant academic research and scientific papers

Rapid and Simple Access to α-(Hetero)arylacetonitriles from Gem-Difluoroalkenes

A scalable cyanation of gem-difluoroalkenes to (hetero)arylacetonitrile derivatives was developed. This strategy features mild reaction conditions, excellent yields, wide substrate scope, and broad functional group tolerance. Significantly, in this reacti

Mechanistic study on iodine-catalyzed aromatic bromination of aryl ethers by N-Bromosuccinimide

Although iodine-catalyzed reaction has rapid advances in recent years, examples on iodine-catalyzed bromination are rare and the mechanism of these reactions remains unclear. Herein, we reported an I2-catalyzed aromatic bromination of aryl ethers by NBS and presented the details of the mechanistic study including kinetic study and the study of kinetic isotope effects. The study revealed that the reaction was actually catalyzed by IBr formed in the induction period, and the rate-determining step was the HBr-elimination of the Wheland intermediate assisted by IBr.

TRIAZOLONE COMPOUNDS AND USES THEREOF

The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.

Design and Synthesis of New Naphthalenic Derivatives as Ligands for 2-Iodomelatonin Binding Sites

New melatonin-like agents were designed from the frameworks of 2,5-dimethoxyphenethylamine, an important structural moiety for the 5-HT receptor, and (2-methoxynaphthyl)ethylamine.The compounds were synthesized by classical methods and evaluated in binding assays with chicken brain membranes using 2-(125I>iodomelatonin as the radioligand.Preliminary studies on the series of N-acyl-disubstituted phenethylamines showed the favorable role of the methoxy group in the ortho position of the side chain on the affinity for the receptor ( Ki = 8 +/- 0.2 nM ) for N-propionamide (3o).This effect was confirmed in a series of the naphthalene derivatives, a bioisosteric moiety of the indole ring, and several potent ligands for melatonin binding sites were prepared such as N-propionamide (4b) ( Ki = 0.67 +/- 0.05 nM ) and N-cyclopropylformamide (Ki = 0.05 +/- 0.004 nM ( (4k).Structure-activity relationships are discussed with regard to melatonin and bioisosteric naphthalenic compound 2.The Ki value for 4b was affected to a similar extent to that of melatonin by GTP-γ-S or Mn2+ in competition experiments, suggesting an agonist profile for this compound.